Protembis GmbH received €20 million (US$21.66 million) in financing from the European Investment Bank to develop its cerebral embolic protection system, Protembo. The intra-aortic filter device deflects embolic material away from arteries leading to the brain during left-sided heart procedures including transcatheter aortic valve replacement.
The $80 million in financing that Huma Therapeutics Ltd. recently raised is a testament to where the company is and what it achieved at a time when the digital health industry is struggling to raise significant financing, Mert Aral, chief medical officer at Huma, told BioWorld.
Deepc GmbH recently raised a further $13 million in a series A extension round to close the round at $26 million for its artificial intelligence (AI)-based operating system, Deepcos, which is designed to provide radiologists with a wide variety of AI-based solutions.
The first economic modelling of Boston Scientific Corp.’s pulsed field ablation system in U.K.’s National Health Service showed that it is more cost-effective as a treatment for paroxysmal atrial fibrillation compared to standard cryoablation.
Tricares SAS raised $50 million in a series D financing round to support upcoming clinical trials in the U.S. and EU for its transfemoral tricuspid heart valve replacement system, Topaz.
Swiss scientists developed hydrogel implants that could help prevent and treat endometriosis by blocking the fallopian tubes and stopping the passage of endometrial cells. The implants, though in their early stage of development, bode well for the millions of women suffering from the chronic condition.
Magenta Medical Ltd. raised $105 million in financing that will go toward clinical trials and to secure U.S FDA approval for its Elevate system, the world's smallest heart pump. The substantial investment haul was “a vote of confidence” from the investor community for what the company is doing, David Israeli, CEO of Magenta told BioWorld.
Spotlight Medical SAS recently raised €6.2 million (US$6.7 million) in seed funding to bring its first artificial intelligence-powered cancer test to the market as it looks to transform treatment of the disease. “We believe our personalized testing approach will revolutionize cancer treatment, providing everyone with the best possible chance to beat cancer,” Sylvain Berlemont, CEO of Spotlight told BioWorld.
There is no doubt that artificial intelligence, automation and robotics are transforming today’s laboratories. At the forefront of these changes is Automata Technologies Ltd., which has developed the Linq platform to digitally and robotically connect all the components of a modern life sciences lab to create fully automated end-to-end workflows.
GE Healthcare Technologies Inc. entered into a conditional agreement to acquire the clinical AI business of Intelligent Ultrasound Group plc for £40.5 million (US$51 million). The deal is part of GE Healthcare’s effort to bolster its portfolio of artificial intelligence-enabled devices and strengthen its ultrasound business.
